YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Annexon Biosciences BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that…
Strategic Execution and Platform Validation Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management is pivoting to a dual primary e…
Key Points Interested in Annexon, Inc.? Here are five stocks we like better. Annexon expanded the ARCHER II trial of vonaprument in geographic atrophy to include an independent 24-month endpoint, while maintaining its planned fourth-quarte…
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 mill…
(RTTNews) - Today's biotech movers include Apollomics following its return to Nasdaq compliance, Iovance and AVITA ahead of Q2 earnings updates, Annexon, awaiting topline data in dry age-related macular degeneration with geographic atrophy…
BRISBANE, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 mill…
Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying high growth tech stocks involves looki…
Over the last 7 days, the United States market has risen by 2.2% and is up 31% over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this favorable environment, identifying high growth tech stocks in…
Annexon Inc. (NASDAQ:ANNX) is one of the small cap stocks with the highest upside potential. On March 30, the company reported its 2025 year-end financial results, highlighting a period of significant clinical and regulatory progress for i…
Annexon Biosciences (NASDAQ:ANNX) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s shares have skyrocketed by 289.29% over the past year and by 39.45% year-to-date. On April 16, Needham analyst Joseph…
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 mill…
Annexon Biosciences BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that i…
Bet_Noire / iStock via Getty Images Quick Read Stocks continued higher on Monday as the “Santa Claus” rally appears to be here. Small-caps were the big winner Monday as the Russell 2000 pushed higher again. Look for trading volume to reall…
Annexon Inc. (NASDAQ:ANNX) is one of the best multibagger penny stocks to buy right now. On December 1, Clear Street initiated coverage of Annexon Inc. (NASDAQ:ANNX) with a Buy rating and a $17 price target. The positive stance is in respo…
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated disease…
As the U.S. market grapples with fluctuating indices and AI bubble concerns, the Dow Jones Industrial Average recently hit an all-time high before retreating, while tech-heavy stocks like those in the Nasdaq face pressure amid broader econ…
mezzotint / Shutterstock.com Quick Read December trading started off with a “risk off” session on Monday, with all major indices ending the day lower. After another year of double-digit gains for stocks, investors are clearly ready to take…
Annexon, Inc. (NASDAQ:ANNX) is one of the 12 hot penny stocks to invest in right now.Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement On November 19, 2025, The Fly reported that Wells Fargo increased its price targe…
[Stock market trading, financial data graph chart, data visualization, Business arrow graph chart] Rasi Bhadramani * Annexon (ANNX [https://seekingalpha.com/symbol/ANNX]) stock rose after the company's director disclosed a purchase of shar…
BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated disease…
The United States market has recently experienced mixed performances, with the Dow Jones Industrial Average declining for two consecutive days while technology shares have shown signs of rebounding. Amidst these fluctuations, investors are…
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated disease…
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the bod…
Annexon, Inc. (NASDAQ:ANNX) is among the best fast money stocks to buy now. During the first quarter, Nuveen LLC acquired a new position in Annexon, Inc. (NASDAQ:ANNX) through the purchase of 23,491 shares of the company’s stock. According…
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neur…
Key Points Annexon reported a GAAP net loss per share of $0.34 for Q2 2025, narrower than the consensus GAAP estimate of $(0.37). Research and development expenses climbed 76.8% year over year (GAAP). reflecting the advancement of the comp…
* Annexon Biosciences press release [https://seekingalpha.com/pr/20201908-annexon-reports-second-quarter-2025-financial-results-portfolio-progress-and-key-anticipated] (NASDAQ:ANNX [https://seekingalpha.com/symbol/ANNX]): Q2 GAAP EPS of -$…
BRISBANE, Calif. - Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company with a current market capitalization of $260 million and a strong liquidity position according to InvestingPro data, announced Thursday that its eye…
Director William H. Carson purchased 4,115 shares of Annexon Inc . (NASDAQ:ANNX) on July 30, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at a weighted average price of $2.43, in a…
(RTTNews) - Annexon Inc. (ANNX) today announced that it has achieved a key clinical milestone by completing enrollment in its phase III trial of Vonaprument for dry age-related macular degeneration with geographic atrophy. The phase III tr…
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science…
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program…
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuro…
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster…
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuro…
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcar…